Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Psilocybin - Revive Therapeutics

Next Previous
Search
Drug Profile

Psilocybin - Revive Therapeutics

Alternative Names: Psilocybine - Revive Therapeutics; PSY-0.1; PSY-0.2; PSY-0.3; PSY-0.4/0.5; PSY-0.6

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Psilocin Pharma Corp
  • Developer PharmaTher; Psilocin Pharma Corp; Revive Therapeutics; University of Wisconsin-Madison
  • Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
  • Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Substance-related disorders
  • Preclinical Neurological disorders; Psychiatric disorders; Stroke; Traumatic brain injuries
  • No development reported Anxiety disorders; Bipolar disorders; Cancer; Depressive disorders; Eating disorders; Opioid-related disorders; Unspecified

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for research development in Cancer in Canada
  • 12 Nov 2024 Preclinical trials in Stroke in Canada (unspecified route)
  • 12 Nov 2024 Pharmacodynamics data from a preclinical study in Stroke released by Revive therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top